Myocardial ion channels and membranes

Myocardial ion channels and membranes refers to the integrated system of integral membrane proteins and the lipid bilayer of cardiac myocytes that coordinate the heart's electrical activity (StatPearls, 2023). This system includes voltage-gated sodium channels (e.g., Nav1.5), various potassium channels (e.g., hERG, KvLQT1), and L-type calcium channels (e.g., Cav1.2), which together generate the cardiac action potential (NCBI, 2022). The sarcolemmal membrane acts as a scaffold for these channels and maintains the ionic gradients necessary for excitability and contraction (PubMed, 2021). These components are the primary targets for antiarrhythmic drugs, which are classified based on their specific effects on these channels (StatPearls, 2023). Mutations in the genes encoding these channels lead to inherited channelopathies like Long QT syndrome, while acquired dysfunction is a hallmark of heart failure and ischemia (NIH, 2023). Pharmacological modulation of these targets aims to stabilize the membrane potential and prevent life-threatening arrhythmias, but it requires precise dosing to avoid proarrhythmic complications (PubMed, 2022). Consequently, clinical management often involves continuous ECG monitoring to track changes in conduction and repolarization (StatPearls, 2023).

Other names

Cardiac ion channelsSarcolemmal ion channelsMyocardial membrane proteinsCardiac sarcolemmaCardiac electrophysiological targets

Drugs targeting this group act by binding to and inhibiting specific voltage-gated ion channels (sodium, potassium, or calcium) or ion-transporting ATPases, thereby altering the electrical properties of the myocardial cell membrane to suppress abnormal rhythms (StatPearls, 2023).